These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20021455)

  • 81. The E2F family and the role of E2F1 in apoptosis.
    Wu Z; Zheng S; Yu Q
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2389-97. PubMed ID: 19539777
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation.
    Pickering MT; Kowalik TF
    Oncogene; 2006 Feb; 25(5):746-55. PubMed ID: 16186801
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 84. E2F1-mediated apoptosis as a target of cancer therapy.
    Wu Z; Yu Q
    Curr Mol Pharmacol; 2009 Jun; 2(2):149-60. PubMed ID: 20021455
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
    Engelmann D; Pützer BM
    Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
    Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
    Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
    [TBL] [Abstract][Full Text] [Related]  

  • 87. E2F1 apoptosis counterattacked: evil strikes back.
    Pützer BM; Engelmann D
    Trends Mol Med; 2013 Feb; 19(2):89-98. PubMed ID: 23219173
    [TBL] [Abstract][Full Text] [Related]  

  • 88. E2F1 death pathways as targets for cancer therapy.
    Pützer BM
    J Cell Mol Med; 2007; 11(2):239-51. PubMed ID: 17488475
    [TBL] [Abstract][Full Text] [Related]  

  • 89. E2F1 pathways to apoptosis.
    Ginsberg D
    FEBS Lett; 2002 Oct; 529(1):122-5. PubMed ID: 12354623
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The E2F1-miRNA cancer progression network.
    Knoll S; Emmrich S; Pützer BM
    Adv Exp Med Biol; 2013; 774():135-47. PubMed ID: 23377972
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
    Laine A; Westermarck J
    Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
    [TBL] [Abstract][Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.